DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment

 

Business Affairs Homepage

Survey finds medical devices not meeting provider expectations A call for higher-quality clinical evidence, flexible contract options and better customer service

European Society of Radiology calls for diagnostics to be better represented in value-based care Diagnosis 'is the basis for any treatment decision'

Canon elaborates on financial goals with Toshiba Medical in the fold 'Launching into the global health market ... in one fell swoop'

Former Cleveland Clinic Innovations director pleads guilty to fraud Scheme cost the institution over $2.7 million

NuVasive files lawsuit against former vice chairman Alleges breach of fiduciary duties and violation of contractual obligations

Blue Earth Diagnostics inks Axumin deal with Seibersdorf Laboratories Manufacturing and distribution in certain European countries

Philips to halt production of external defibrillators in two U.S. facilities OEM looks ahead, calling consent decree 'consequence of past sins'

2017 AARC Congress: Focus on COPD For four days in Indianapolis, patients took center stage

Amazon may decide to sell prescription drugs online by Thanksgiving Supply chain and regulatory hurdles could make it more trouble than it's worth

Lynn O'Connor Vos Muscular Dystrophy Association appoints CEO

Sofie Biosciences has acquired Zevacor
Pharma in a deal that unites the two
as one company, SOFIE

Eyeing theranostics, Sofie Biosciences completes acquisition of Zevacor Pharma

par John Fischer , Staff Reporter
Sofie Biosciences has acquired Zevacor Pharma in a deal that combines the two companies under the rebranded name, SOFIE.

The agreement combines Zevacor Pharma’s 16 radiopharmacies and contract manufacturing organization that supports clinical trials with the imaging and radiochemistry products of Sofie Biosciences, allowing both together to offer both clinical and life science services. The name change reflects this combination of services.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“Now is the right time to buy Zevacor Pharma because we see a wave of new products that will be adopted, with the most significant market being these new theranostics that are coming online, beginning first with neuroendocrine tumor imaging and therapy and then followed up by prostate cancer imaging and therapy,” Patrick Phelps, the president and CEO of SOFIE, told HCB News. “This theranostic market that lies out in front of us is going to be huge, and Zevacor is one of the main suppliers for theranostics.”

Aside from new theranostic products, the acquisition is also based on the notion that FDG, though underutilized, will continue to grow due to the use of FDG PET in treatment monitoring, and that the addition of studies of amyloid PET in patient management for Alzheimer’s disease will help spur the growth of amyloid imaging.

Sofie Biosciences raised a $27.4 million round to fund the acquisition and capitalization of the Zevacor Pharma, uniting the two as SOFIE.

Customers of Sofie Bioscience will have access to a variety of imaging probes and tracers to offer as new applications to scientists for their facilities. Its radiology technologies will be innovated into commercial radiopharmacies, allowing for quicker translation of new tracers from academic labs to commercial pharmacies in support of early trials.

Zevacor Pharma customers will have access to new tracers, as well as new therapies and theranostics, before they are FDA approved or available at other commercial pharmacies.

SOFIE will continue to scale the production of FDG PET scans as well as a variety of recently approved FDA products, and will be involved in clinical trials early on, compared to conventional radiopharmacies which usually only offer FDG and one or two FDA-approved products and may get involved in clinical trials in the late stages.

“I think that with SOFIE taking over Zevacor, people will see us as the group that will help drive a lot of these new scans, these new therapies, to the market, and see us as very forward-looking,” said Phelps.

Zevacor Pharma did not return calls for comment.

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Publicité
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2017 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS